BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/15/2023 6:05:28 AM | Browse: 173 | Download: 562
 |
Received |
|
2022-12-28 20:40 |
|
Peer-Review Started |
|
2022-12-28 20:42 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-02-16 23:38 |
|
Revised |
|
2023-02-17 09:18 |
|
Second Decision |
|
2023-04-23 03:24 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-04-24 02:52 |
|
Articles in Press |
|
2023-04-24 02:52 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-06-09 01:56 |
|
Publish the Manuscript Online |
|
2023-06-15 06:05 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Surgery |
| Manuscript Type |
Review |
| Article Title |
Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Gianluca Cassese, Ho-Seong Han, Yoo‐Seok Yoon, Jun Suh Lee, Boram Lee, Antonio Cubisino, Fabrizio Panaro and Roberto Ivan Troisi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ho-Seong Han, MD, Professor, Department of Surgery, Seoul National University Colllege of Medicine, 166 Gumi-ro, Bundang-gu, Seongnam 13620, Gyeonggi-do, South Korea. hanhs@snubh.org |
| Key Words |
Pancreatic cancer; Pancreatic duct adenocarcinoma; Neoadjuvant chemotherapy; Borderline resectable; Locally advanced pancreatic cancer |
| Core Tip |
Pancreatic adenocarcinoma (PDAC) is one of the most common and lethal human cancers worldwide; yet patients diagnosed with it still have a poor prognosis. Multimodal therapy is one of the most promising treatment options that increase the overall survival. Neoadjuvant chemotherapy (NACT) is recommended for treating borderline resectable PDAC. While recent studies have tried to explore the role of NACT in treating resectable and locally advanced PDAC, novel therapeutic modalities, such as ct-DNA and molecular targeted therapy, may guide both treatment and monitoring during the disease course to improve prognosis. |
| Publish Date |
2023-06-15 06:05 |
| Citation |
Cassese G, Han HS, Yoon YS, Lee JS, Lee B, Cubisino A, Panaro F, Troisi RI. Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives. World J Gastrointest Oncol 2023; 15(6): 911-924 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i6/911.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i6.911 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
